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Abstract
Objective—There are few studies on the natural history of milk allergy. Most are single-site and
not longitudinal, and these have not identified a means for early prediction of outcomes.
Methods—Children aged 3 to 15 months were enrolled in an observational study with either (1)
a convincing history of egg allergy, milk allergy, or both with a positive skin prick test (SPT)
response to the trigger food and/or (2) moderate-to-severe atopic dermatitis (AD) and a positive
SPT response to milk or egg. Children enrolled with a clinical history of milk allergy were
followed longitudinally, and resolution was established by means of successful ingestion.
Results—The cohort consists of 293 children, of whom 244 were given a diagnosis of milk
allergy at baseline. Milk allergy has resolved in 154 (52.6%) subjects at a median age of 63
months and a median age at last follow-up of 66 months. Baseline characteristics that were most
predictive of resolution included milk-specific IgE level, milk SPT wheal size, and AD severity
(all P < .001). Baseline milk-specific IgG4 level and milk IgE/IgG4 ratio were not predictive of
resolution and neither was expression of cytokine-inducible SH2-containing protein, forkhead box
protein 3, GATA3, IL-10, IL-4, IFN-γ, or T-bet by using real-time PCR in CD25-selected, casein-
stimulated mononuclear cells. A calculator to estimate resolution probabilities using baseline milk
IgE level, SPT response, and AD severity was devised for use in the clinical setting. Conclusions:
In this cohort of infants with milk allergy, approximately one half had resolved over 66 months of
follow-up. Baseline milk-specific IgE level, SPT wheal size, and AD severity were all important
predictors of the likelihood of resolution.
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Milk allergy is the most common food allergy in young children, with prevalence rates
estimated in the range of 2% and 3%.1,2 Although the natural history of milk allergy is
generally favorable, with the majority of children showing resolution during childhood, prior
studies have yielded widely varying results as to the rate of resolution.3-16 A recent study
suggested that the natural history of milk allergy might have changed over time, with slower
rates of resolution and a higher proportion of children with disease persisting into
adolescence and even adulthood.15 Although these changes might be real, most differences
between studies are more likely related to both study design and the specific population
under investigation. For example, studies of the general population,11 especially if oral food
challenges are performed at regular intervals, are more likely to demonstrate earlier
resolution than studies of tertiary referral populations.3,9,10,15
The Consortium of Food Allergy Research enrolled infants with likely egg or milk allergy
but without previously known peanut allergy in an observational study to address the
immunologic, genetic, and environmental factors that affect the natural course of food
allergy.17 The primary aim of this analysis was to assess the natural history of milk allergy
in the infants enrolled in this cohort with a diagnosis of milk allergy, with a particular focus
on the clinical factors predicting the resolution of milk allergy over the first 5 years of life.
METHODS
Subjects, study definitions, and procedures
The subjects of this study are a subset of a larger cohort of 512 infants originally enrolled at
3 to 15 months of age at 5 sites: Mount Sinai School of Medicine, New York, New York;
Duke University Medical Center, Durham, NC; Johns Hopkins University School of
Medicine, Baltimore, Maryland; National Jewish Health, Denver, Colorado; and Arkansas
Children’s Hospital, Little Rock, Arkansas, as described previously17; the North Carolina
subjects moved with the investigative team from Duke to the University of North Carolina–
Chapel Hill in March 2012. Enrollment criteria for the whole cohort were designed to obtain
atopic children with likely egg or milk allergy at risk for peanut allergy but without current
peanut allergy. Briefly, enrollment required either (1) a history of a convincing immediate
allergic reaction to cow’s milk (and/or egg) and a positive skin prick test (SPT) response (3
mm larger than that elicited by the negative control) to cow’s milk (and/or egg, if the clinical
reaction was to egg) and/or (2) moderate-to-severe atopic dermatitis (AD) and a positive
SPT response to milk, egg, or both.
The subgroup of children in the current study had a diagnosis of milk allergy at the time of
enrollment or acquired this diagnosis after enrollment with no prior evidence of tolerance of
milk (eg, enrollment diagnosis was uncertain). Study procedures were reviewed and
approved by a National Institute of Allergy and Infectious Diseases Data Safety Monitoring
Board and by local institutional review boards, and written signed consent forms were
obtained.
Participants were considered to have milk allergy if they had either (1) a positive physician-
supervised oral food challenge result or a convincing reaction (defined by symptoms within
an hour of isolated ingestion that included at least urticaria and/or angioedema, difficulty
breathing, wheezing, throat tightness, and/or vomiting) and sensitization to milk (milk-
specific IgE level ≥0.35 kUA/L and/or SPT response >3 mm) or (2) a flare of AD associated
with milk ingestion along with a milk-specific IgE level of greater than 5 kUA/L,18 which is
greater than 95% predictive of milk allergy in infants. Reactions to goat’s or sheep’s milk
were also considered evidence of cow’s milk allergy. Subjects were considered milk tolerant
if they ingested whole uncooked milk products (milk, yogurt, or ice cream) in serving size
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quantities without symptoms either during physician-supervised oral food challenges or after
introduction at home. Dietary ingestion of products with extensively heated milk (baked
milk, for example as an ingredient in a muffin) was queried but was not considered evidence
of resolved milk allergy.
Dietary, medical, and social histories were obtained by using questionnaires completed
during enrollment interviews. A diagnosis of asthma and allergic rhinitis was based on
parental report or parental report of a physician’s diagnosis. A diagnosis of other food
allergies included per-protocol definitions for egg and peanut,17 whereas for other foods,
this was based on a clinical diagnosis by a study physician.
Diagnosis of AD required pruritus and an eczematous rash (acute, subacute, or chronic) with
typical morphology and age-specific patterns, a chronic or relapsing history, atopy (personal
history, family history, or both or IgE reactivity), and xerosis. AD severity was graded based
on criteria previously described and published by Rajka and Langeland.19 Briefly, the AD
severity was graded as mild, moderate, or severe by using the following parameters (see
Table E1 in this article’s Online Repository at www.jacionline.org) 19 to compute a score
summation: (1) extent of disease (by “rule of nine” based on the proportion of body surface
area with active disease), (2) course of disease (defined by history as >3 months in remission
in the past year, ≤3 months in remission but not continuous, or continuous remission over
the past year), and (3) intensity of disease (defined as mild itch rarely disturbing sleep,
severe itch usually disturbing sleep, or intermediate itch/sleep disturbance), each on a 3-
point scale. Summation scores of 3 to 4 indicated mild disease, 5 to 7 indicated moderate
disease, and 8 to 9 indicated severe disease. Atopic disease history in parents of the enrolled
infants was based on previously published definitions and was recorded by parental report.20
The study design includes evaluations, care for food allergy, and instructions on dietary
management that were uniform among the 5 clinical centers and reflect practice parameters
for AD,21 food allergy,22 and the American Academy of Pediatrics recommendations for
allergy prevention published in 2000 to maintain uniformity and an observational
approach.23 Participants were evaluated in person at enrollment, 6 months, 12 months, and
yearly thereafter, with additional telephone follow-up between each visit and instructions to
contact the study site for any allergic reactions, at which time additional details were
obtained.24
SPTs
SPTs were performed with the GreerPick (Greer Laboratories, Lenoir, NC), with
participants avoiding antihistamines for at least 5 half-lives of the specific agent. Tests were
performed on the infant’s back, and at 15 minutes, the wheal was outlined in pen and
transferred by tape to paper. The size of the longest diameter and its longest perpendicular
were averaged. An SPT score was computed by subtracting the saline control measure, and a
positive SPT response was defined by a score of 3 mm or greater. Tests were considered
reliable if the wheal of the negative control (50% glycerin-saline) was 3 mm or smaller and
wheal size elicited by the histamine control was at least 3 mm larger than the wheal size
elicited by the negative control. All sites used the same lot of reagents, and training was
performed to ensure consistency. The cow’s milk extract was obtained from Greer (catalog
no. F293).
Serum milk-specific IgE and IgG4 levels
The concentration of specific IgE antibody to milk was measured from plasma at a central
laboratory (Mount Sinai) by using the Phadia (now Thermo Fisher Scientific, Waltham,
Mass) ImmunoCAP system and reported in kilounits of allergen per liter. A level of 0.35
Wood et al. Page 3













kUA/L or greater was considered positive. The concentration of IgG4 antibodies to milk was
also measured from plasma samples by using the Phadia ImmunoCAP system. The detection
limit for IgG4 is 0.07 mg/L.
Mononuclear cell stimulation and PCR analysis
PBMC isolation was performed with Ficoll-Paque density gradient centrifugation, and
cultures were performed at each clinical site on fresh venous blood samples, as previously
described.1 Briefly, 4 million cells per condition were cultured for 48 hours in AIM-V
serum-free media (Invitrogen, Carlsbad, Calif) with purified α-, β-, and κ-caseins (50 μg
each/L), and control stimulations were performed with medium alone (negative) and anti-
CD3/anti-CD28 beads (positive). At the end of the culture period, cells expressing CD25
were enriched by means of selection with anti-CD25–coated paramagnetic beads, according
to the manufacturer’s protocol (Miltenyi Biotech, Bergisch Gladbach, Germany). Pilot
experiments demonstrated approximately 10-fold enrichment of CD25+ cells, with 70% to
80% of selected cells coexpressing CD3, CD4, and CD25, as measured by using flow
cytometry. The entire selected fraction of cells was immediately lysed in RLT buffer
(Qiagen, Hilden, Germany) and stored at −80°C until RNA purification. The quantitative
PCR was carried out in the central laboratory according to the in-house established protocol
by using SYBR Green I fluorescence detection in a 384-well plate on the ABI 7900
(Applied Biosystems, Foster City, Calif). Raw PCR analysis and annotation were performed
on coded samples. The cycle threshold (Ct) number was set by software, with confirmation
and adjustment as necessary to define the threshold of linear amplification. For the gene
expression data, ΔΔCt was calculated by subtracting the RPS9 reporter gene Ct value and
then normalizing by subtracting the standardized medium control response. Negative values
indicate relatively higher activity with a unit score change corresponding to a doubling.
Nondetected genes were arbitrarily assigned a Ct value of 40.
Statistical analysis
Time to resolution of milk allergy was measured with age as the time metric. Although the
time of allergy diagnosis varied depending on when food introduction and diagnostic testing
were performed, each subject’s first definitive diagnosis was positive for milk allergy. Those
subjects (n = 12) who had resolution of their milk allergy before 15 months were assigned a
value of 15 months. Because enrollment continued through 15 months, this permitted the use
of fixed covariate baseline modeling in all participants.
Distributional differences in baseline variables were compared with the χ2 statistic.
Proportional hazards regression models were fit to examine covariates for their effect on the
hazard or risk function.25 The estimated survival distribution was calculated from the
relative hazard (RH), which is the exponentiated sum of the linear combination of the
products of the parameter estimates with their respective clinical characteristics. The
common underlying empiric cumulative hazard function λ(t) is estimated with a step
function, and the resolution curve is estimated as follows:
In this article hazard refers to the risk of a beneficial event, namely allergy resolution, and
variables are structured so that large relative hazard values are associated with increased
chance of allergy resolution. Model prediction capability for baseline variable models was
summarized with the C index, a concordance measure of predicted and observed responses
related to the Kendall rank correlation τ value.26,27 This measure extends the binary end
point assessment of the area under the receiver operating characteristics curve to use with
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time-to-event data. The C index ranges up to 1, and a value of 0.5 indicates no predictive
ability. Time-varying clinical covariate analyses used the most recent available assessment
in the model, and nonproportional hazards were examined by fitting linear and spline
function interactions with time. For real-time PCR variables, an additional assessment of
change from baseline was performed with scores of −1 when 4 or fewer doublings occurred
relative to baseline, 1 when 4 or more doublings relative to baseline occurred, and 0
otherwise. Reported P values are 2-tailed, when applicable, and SAS 9.2 (SAS, Institute,
Cary, NC) and R software were used for computations.
RESULTS
Of the 512 enrolled infants, the cohort with milk allergy consisted of 293 children, of whom
244 were given a diagnosis of milk allergy at baseline. Among the remaining 49 children,
the diagnosis was categorized as uncertain at their entry visit, but milk allergy was
subsequently confirmed. Key baseline characteristics are summarized in Table I. A majority
(178/293) of subjects were enrolled between 6 and 12 months of age; 192 were male, and
101 were female. AD was present in 261 subjects and was categorized as mild in 34,
moderate in 146, and severe in 81. Twenty-four infants were given a diagnosis of milk
allergy based on AD criteria, whereas the remainder had a history of an acute reaction to
milk. One hundred seventeen (39.9%) subjects were also given diagnoses of other food
allergies at their initial evaluation, and another 74 (25.3%) had other food allergies over the
period of observation.
One hundred fifty-four (52.6%) of the 293 participants have now resolved their milk allergy,
with a median age of resolution of 63 months and a median age at last follow-up of 66
months (Fig 1). All but 6 subjects had follow-up beyond 4 years of age. Resolution was
defined by means of oral food challenge in 56 subjects and by successful home introduction
of uncooked milk products in 98 subjects. At the 5-year time point, 32 (20.6%) of 155
subjects with unresolved allergy reported tolerating at least some baked milk products,
whereas 7 reported reactions to ingestion of baked milk products.
Additional baseline characteristics of the cohort, comparing those with and without milk
allergy resolution, are presented in Table I. The baseline characteristics that were most
predictive of milk allergy resolution included milk-specific IgE level, milk SPT wheal size,
and AD severity. Specifically, highly significant differences (P < .001) in the rate of
resolution were noted when comparing those subjects with baseline milk-specific IgE levels
of less than 2 kUA/L, 2 to 10 kUA/L, and 10 kUA/L or greater (Fig 2). For example, greater
than 70% of those in the lowest milk-specific IgE category had resolved milk allergy
compared with only 23% of those in the highest category. Significant differences (P < .001)
in resolution were also predicted by baseline SPT results, as shown in Fig 3, which
represents a comparison of subjects with wheal sizes of less than 5 mm, 5 to 10 mm, and
greater than 10 mm. In addition, marked differences in resolution (P < .001) were detected
when comparing those infants presenting with milk allergy who had no or mild AD with
those with moderate-to-severe AD (Fig 4). However, baseline milk-specific IgG4 levels
were not at all predictive of resolution (see Fig E1 in this article’s Online Repository at
www.jacionline.org), and the milk-specific IgE/IgG4 ratio did not add further insight to the
analyses (data not shown).
Cox regression analyses were conducted to further define the effects of these baseline
variables on milk allergy resolution (Table II). Again, milk-specific IgE level, SPT wheal
size, and AD severity stand out as the most important factors predicting resolution of milk
allergy. For example, when analyzing milk-specific IgE level as a categorical variable,
subjects with baseline levels of less than 2 kUA/L have a 5.74-fold increased hazard ratio of
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resolving their allergy versus those with levels of greater than 10 kUA/L. This analysis also
revealed a nonsignificant trend toward higher rates of resolution in female versus male
subjects. Other variables, such as parental atopic history, education, income, and presence of
siblings, were examined, and none were statistically significant predictors (data not shown).
Serial measurements of milk-specific IgE levels, SPT results, and AD severity were
available to assess the significance of later results, changes over time in these variables, or
both on outcomes of milk allergy (see Table E2 in this article’s Online Repository at
www.jacionline.org). For both milk-specific IgE level and SPT wheal size, the most recent
assessments were also highly significant (P < .001) predictors of milk allergy resolution,
whereas the associated baseline measure did not significantly contribute to the bivariate
model. For these variables, the current status is therefore also important for prognosis. In
contrast, the most recent AD score was not additionally predictive of milk allergy resolution
when adjusted for the baseline value.
With regard to other atopic diseases, resolution was not associated with other food allergy at
any time point. Resolution was slightly less likely in those who had asthma and rhinitis with
hazard ratios for the time-varying most recent status covariate of 0.639 (P = .043) for asthma
and 0.646 (P = .022) for rhinitis, suggesting that the development of these other atopic
diseases might be associated with a decreased chance of resolution as children age. Not
surprisingly, in a 2-variable time-varying covariate analysis, having baked milk without a
reaction increased the chance of resolution (relative hazard, 4.1; P < .0001), whereas having
a reaction decreased the chance of resolution (relative hazard, 0.28; P = .072).
T-cell studies assessed at baseline demonstrated no relationship between casein-stimulated
expression of cytokine-inducible SH2-containing protein, forkhead box protein 3, GATA3,
T-bet, IL-10, IL-4, and/or IFN-γ and the resolution of milk allergy (data not shown).
Analyses of serial measurements of these markers also did not identify any significant
predictor of milk allergy resolution.
Finally, we used the 3 baseline factors most predictive of milk allergy resolution to develop
a composite score that could be applied to individual patients (see Table E3 in this article’s
Online Repository at www.jacionline.org). For example, as represented in Fig 5, the
likelihood of milk allergy resolution for 3 individual patients is predicted by using a
composite index incorporating their milk-specific IgE levels, SPT wheal sizes, and severities
of AD, with lower limits for IgE set at 0.35 kUA/L and SPT response at 2.5 mm. The C
index for the 3-variable model is 0.724 (0.019 SE), with the single baseline variable
component models ranging from 0.665 for the presence of moderate or severe AD to 0.720
for log milk-specific IgE. We have provided a Web-based calculator that can be used in
counseling individual families as to the possible prognosis of their young (<15 months)
child’s milk allergy (see www.cofargroup.org).
DISCUSSION
In this report we have described the natural history of milk allergy in a cohort of children
enrolled in an observational study with a diagnosis of milk allergy. The study demonstrates a
resolution rate of just more than 50% through age 5 years, which falls somewhere in the
middle of previously published studies.3-16
Review of those prior studies reveals 2 salient points as to why interstudy results can differ
so widely. First, results of studies from general populations are more likely to show a more
favorable prognosis compared with studies of children from referral populations, as are
prospective studies, especially those that include regular evaluations. For example, in a
Danish population-based study, 76% of infants with milk allergy had become tolerant by age
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3 years2 compared with only 19% by age 4 years and 42% by age 8 years in a retrospective
study of a population referred to a tertiary care center.14 It is therefore consistent that our
results fall between these extremes in that although the analysis was prospective, it did
include a population preselected for milk or egg allergy who were evaluated at tertiary
referral centers.
As has been demonstrated in several previous studies,3-10,12-14,16 both milk-specific IgE and
SPT results were highly predictive of outcome. This was even the case at baseline, and these
associations persisted through the period of observation. The relationship of AD to the
natural course of milk allergy has been less clear from prior studies, but in this analysis
moderate-to-severe AD at baseline was highly predictive of persistent disease. There was
also a relationship of borderline significance to coexisting asthma and rhinitis by the end of
the observation period. However, no relationships were noted to milk-specific IgG4, IgE/
IgG4 ratio, or casein-stimulated T-cell studies.
The substantial predictive capacity of milk-specific IgE, SPT wheal size, and AD severity
allowed for the development of a novel algorithm to estimate the natural course of milk
allergy. This composite index has been developed into an equation that can be applied to
young (<15 months) patients presenting to the clinic and has been provided as a Web-based
calculator, as well as a computer application. We believe that this unique tool will benefit
health care providers and patients in providing early guidance as to the likelihood for disease
resolution or persistence.
The strengths of this study include the sample size, the prospective design with re-evaluation
at regular intervals, the inclusion of multiple research sites, and the exceptional follow-up
rate. In addition, this study was the first to include detailed analysis of milk-specific IgG4
levels, as well as casein-stimulated T-cell cytokine responses, at baseline and follow-up.
Although it was somewhat surprising that these studies provided no additional insight into
the immunologic basis for the natural acquisition of milk tolerance, they are an important
contribution to the literature.
Our results are somewhat limited by the fact that oral food challenges were not performed at
protocol-defined intervals in this observational study and that many children were deemed
milk tolerant based on unsupervised home introductions. In addition, the reliability of our
algorithm might differ if different methods are used for SPT and IgE measurements. Finally,
although we clearly demonstrated a relationship between the natural history of milk allergy
and AD severity, we did this by using an AD assessment tool that is not routinely used in
clinical practice. This tool was chosen, recognizing that there is no ideal method for AD
assessment28 but that the Rajka-Langeland tool has the advantage of assessing diseases
activity over time rather than as a single assessment based entirely on physical findings. As
such, we do believe that the 3-step gradation provided by this scale is very likely to correlate
with the typical clinical assessment of AD severity.
An additional limitation was that we did not characterize baked milk consumption in a
rigorous manner, although approximately 20% of those designated as having milk allergy in
our cohort reported consumption of products with baked milk without a reaction. The ability
of a subset of children with milk allergy to consume products with extensively heated milk
appears to be associated with a phenotype of milk allergy that is more likely to resolve, and
resolution can be accelerated by ingesting these foods.29,30 Therefore it is important to
recognize that our overall estimate of resolution does not include at least some children who
might be fully tolerant of even unheated milk or examine whether the introduction of baked
milk might have influenced the natural course of milk allergy in this cohort. Nonetheless,
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the study did not specifically encourage trial or oral food challenge to baked milk products,
and therefore we believe the results reflect clinical practice.
In conclusion, we estimate from this well-characterized cohort that approximately 50% of
children with milk allergy will become milk tolerant by 5 years of age. Resolution is highly
associated with lower milk-specific IgE levels, smaller SPT wheal sizes, and the absence of
significant AD. These highly predictive variables have been used to provide the clinician
with a calculator to predict the natural history of milk allergy for individual patients under
their care, although additional studies to validate the model will be needed.
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Refer to Web version on PubMed Central for supplementary material.
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Clinical implications: Milk allergy is outgrown in a majority of children by school age.
Baseline milk IgE levels and SPT response sizes, along with AD severity, can be used to
predict the natural course of disease.
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Kaplan-Meier analysis of milk allergy resolution over time is shown in blue, with pointwise
95% CIs shown in red.
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Kaplan-Meier analysis representing the relationship of milk allergy resolution to baseline
milk-specific IgE levels. Individual curves represent IgE levels of less than 2 kUA/L (blue),
2 to 10 kUA/L (red), and 10 kUA/L or greater (green).
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Kaplan-Meier analysis representing the relationship of milk allergy resolution to baseline
milk SPT wheal size. Individual curves represent wheal sizes of less than 5 mm (blue), 5 to
10 mm (red), and greater than 10 mm (green).
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Kaplan-Meier analysis representing the relationship of milk allergy resolution to baseline
AD. Individual curves represent no/mild AD (blue) and moderate/severe AD (red).
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This figure represents results of a composite index based on the baseline milk-specific IgE
level, SPT wheal, and severity of AD, which can be used to estimate the likelihood of milk
allergy resolution. For example, the lower curve (red) in this figure represents a patient with
a milk-specific IgE level of 20 kUA/L, an SPT mean wheal diameter of 7 mm, and
moderate-to-severe AD, whereas the middle curve (green) represents a patient with the same
IgE level and skin test score but no or mild AD. The upper curve (blue) represents another
patient with a milk IgE level of 2 kUA/L, an SPT wheal score of 4 mm, and no or mild AD.
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TABLE II
Resolution of milk allergy (Cox regression analysis with 1 variable in the model at a time)
Factor for resolution of milk allergy Hazard ratio 95% Hazard ratio confidence limits P value*
Baseline age (mo)
 3-5 vs 13-15 1.40 0.82-2.36 .378
 6-8 vs 13-15 1.12 0.71-1.76
 9-12 vs 13-15 0.91 0.61-1.35
Sex
 Female vs male 1.28 0.92-1.78 .141
Race
 White vs nonwhite 1.02 0.70-1.48 .909
Baseline milk-specific IgE level (kUA/L)
 <2 vs ≥10 5.74 3.48-9.46 <.001
 2-<10 vs ≥10 2.66 1.56-4.54
Baseline AD
 Mild/none vs moderate/severe 2.09 1.48-2.94 <.001
Baseline milk SPT response (mm)
 <5 vs >10 3.65 2.42-5.51 <.001
 5-10 vs >10 1.86 1.22-2.82
Breast-feeding at entry
 Yes, but no longer vs never 0.94 0.59-1.49 .399
 Yes, currently vs never 0.76 0.46-1.24
Other food allergy
 Yes vs none 0.94 0.68-1.29 .687
Asthma or rhinitis
 Yes vs none 1.30 0.83-2.03 .246
*
P values represent comparisons of all variables in that category.
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